Breaking News, Promotions & Moves

MitoRx Appoints Chief Scientific Officer

Xavier Jacq is a scientist with extensive experience in small molecule drug development and mitochondrial biology.

Author Image

By: Charlie Sternberg

Associate Editor

MitoRx Therapeutics Limited, a platform biotech company developing novel mitochondrial-targeted persulfide modifiers, has appointed Xavier Jacq as Chief Scientific Officer (CSO). “Welcoming Xavier to MitoRx cements our position as the leading biotech company developing mitochondrial-targeted therapeutics,” said Jon Rees, CEO, MitoRx. Experience Jacq is a scientist with extensive experience in small molecule drug development and mitochondrial biology. He was most recently CSO at Moa Tech...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters